Adagene (ADAG) Interest Expenses (2019 - 2026)
Adagene (ADAG) posted quarterly Interest Expenses of $1.7 million for Q4 2025, down 91.84% year-over-year from $20.3 million in Q4 2024, and down 18.87% quarter-over-quarter from $2.0 million in Q2 2025.
Adagene (ADAG) Interest Expenses (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Interest Expenses for 7 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses fell 91.84% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (down 91.84% YoY), while the FY2025 annual figure was $20.4 million, changed 0.43% from the prior year.
- Interest Expenses slipped to $1.7 million in Q4 2025 per ADAG's latest filing, from $2.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $20.3 million in Q4 2024 and bottomed at $94990.0 in Q4 2022.
- Historically, Interest Expenses has averaged $4.6 million across 5 years, with a median of $2.0 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses tumbled 96.37% — and 2023, when it soared 2017.95%.
- Adagene's Interest Expenses stood at $2.6 million in 2021, then sank by 96.37% to $94990.0 in 2022, then jumped by 2017.95% to $2.0 million in 2023, then surged by 910.84% to $20.3 million in 2024, then plunged by 91.84% to $1.7 million in 2025.
- Business Quant data shows ADAG's Interest Expenses at $1.7 million in Q4 2025, $2.0 million in Q2 2025, and $20.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 25.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.20 Mn |
| Jun 30, 2026 | 25.20 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Dec 31, 2024 | 20.34 Mn |
| Dec 31, 2024 | 20.34 Mn |
| Jun 30, 2024 | 6.94 Mn |
| Jun 30, 2024 | 6.94 Mn |
| Dec 31, 2023 | 2.01 Mn |
| Dec 31, 2023 | 2.01 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Dec 31, 2022 | 94,990.00 |
| Dec 31, 2022 | 94,990.00 |
| Dec 31, 2021 | 2.62 Mn |
| Dec 31, 2021 | 2.62 Mn |
| Dec 31, 2020 | 33.41 Mn |
| Dec 31, 2020 | 33.41 Mn |